Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11032MR)

This product GTTS-WQ11032MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2&ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3; NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 2065
UniProt ID P04626; P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11032MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ549MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ6542MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ8476MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ11877MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ15453MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ11689MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ1587MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ125MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 11F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW